Trazodone is prescribed for anxiety, but it is not approved for that purpose. The FDA has only ever cleared trazodone for major depressive disorder, which means every anxiety-related prescription is off-label. Despite this, a 2019 analysis of U.S. prescription data found that about 6% of all single-diagnosis trazodone prescriptions were written specifically for anxiety disorders. That share is small compared to the roughly three-quarters written for insomnia, but it still represents hundreds of thousands of prescriptions a year. The clinical evidence behind this practice is thin in places and surprisingly encouraging in others, and the gap between how the drug is used and what has been formally studied is worth understanding.
Why Doctors Prescribe It Off-Label for Anxiety
Off-label prescribing of psychoactive drugs is common in psychiatry and general practice alike. A major driver is that many psychiatric medications affect overlapping brain systems, so a drug approved for one condition often shows activity against related symptoms. Trazodone fits this pattern well: it was developed as an antidepressant, but its pharmacology touches several pathways linked to anxiety.1The Journal of Psychiatry & Law. Off-label Prescribing of Antidepressants and Anxiolytics: An Attorney’s Guide to Psychoactive Drugs In practice, clinicians reach for trazodone when they want something that can calm anxiety and improve sleep without the dependence risk that comes with benzodiazepines. Its sedating properties make it especially attractive when a patient’s anxiety is tangled up with insomnia, which is often the case.
The scale of off-label use is striking. In a study of 2019 U.S. prescribing data, over 91% of trazodone prescriptions with a single assigned diagnosis were for conditions other than depression. Insomnia dominated at nearly 74%, anxiety disorders accounted for about 6%, and depression, the only approved indication, came in at just 8.4%.2Health Affairs Scholar. Off-label policy through the lens of trazodone usage and spending in the United States Trazodone is, in a real sense, a sleep medication that happens to be labeled as an antidepressant. Its use for anxiety sits somewhere in between: more studied than its use for insomnia in some ways, but far less commonly prescribed.
How Trazodone Acts on Anxiety at the Brain Level
Trazodone’s anti-anxiety effects come from a different mechanism than its antidepressant activity. The drug blocks serotonin receptors known as 5-HT2A and 5-HT2C, which play a role in regulating mood, anxiety, and sleep. By blocking these receptors, trazodone reduces anxiety and agitation while making more serotonin available in the brain’s signaling pathways. It also blocks alpha-1 adrenergic receptors, which helps dampen the physical side of anxiety: the racing heart, the restlessness, the heightened fight-or-flight response that can feel overwhelming during a panic attack or anxious episode.3PubMed Central. Targeting heterogeneous depression with trazodone prolonged release: from neuropharmacology to clinical application
This dual action, calming both the mental churn of worry and the physical symptoms of arousal, is part of what makes trazodone appealing for anxiety even though first-line treatments like SSRIs work through somewhat different pathways. SSRIs boost serotonin broadly by preventing its reabsorption; trazodone works more selectively on specific receptor subtypes. Whether that selectivity translates into a meaningful clinical advantage for anxiety is less clear-cut than the pharmacology alone might suggest.
Dose Matters More Than You Might Think
One of the more underappreciated aspects of trazodone is how dramatically its effects change depending on the dose. At low doses, around 50 mg, the drug primarily blocks histamine and serotonin receptors involved in wakefulness, which is why it puts people to sleep so effectively. At these doses, the antidepressant and anxiolytic effects are minimal. Higher doses are needed to engage the serotonin reuptake inhibition that drives its mood and anxiety benefits.4PubMed. Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets
This matters because many patients are prescribed trazodone at low, sleep-promoting doses (25 to 100 mg at bedtime) and then wonder why their anxiety hasn’t improved. If the goal is genuinely to treat an anxiety disorder and not just to help someone fall asleep, the dose usually needs to be in the range used for depression, often 150 mg or higher. The key clinical trial for anxiety used a mean dose of 255 mg. The sleepiness that makes low-dose trazodone popular as a sleep aid can become a burden at those higher doses, which is one reason clinicians sometimes hesitate to push the dose upward.
The Strongest Trial Evidence for Generalized Anxiety
The most rigorous direct evidence for trazodone as an anxiety treatment comes from a randomized, double-blind, placebo-controlled trial comparing trazodone with imipramine, diazepam (Valium), and placebo in patients with generalized anxiety disorder. From the third week through the eighth week of treatment, trazodone performed comparably to diazepam, with both drugs clearly outperforming placebo. Imipramine did somewhat better than either. Among patients who completed the full trial, about 69% of those on trazodone showed moderate to marked improvement, compared with 66% on diazepam and only 47% on placebo. The antidepressants were especially effective against the psychological symptoms of anxiety, such as tension, apprehension, and persistent worry, rather than just the physical symptoms.5JAMA Psychiatry. Antidepressants for the Treatment of Generalized Anxiety Disorder: A Placebo-Controlled Comparison of Imipramine, Trazodone, and Diazepam
This is a meaningful result, and it is one of the reasons trazodone keeps showing up in clinical practice for anxiety. But it is also essentially a single well-designed trial from the early 1990s, and the evidence base hasn’t deepened much since then. Earlier reviews also noted that trazodone appeared comparable to benzodiazepines like diazepam and chlordiazepoxide in patients with anxiety, though those studies were more limited in scope.6PubMed. Trazodone: a review of its pharmacological properties and therapeutic use in depression and anxiety The research community has largely moved on to studying SSRIs and SNRIs for anxiety, leaving trazodone in a peculiar position: plausibly effective, somewhat proven, but far from thoroughly tested against modern alternatives.
How Trazodone Compares to SSRIs
SSRIs like sertraline (Zoloft) and escitalopram (Lexapro) are the standard first-line treatment for most anxiety disorders. They have decades of large trial data behind them and well-established dosing guidelines. Trazodone simply does not have that depth of evidence for anxiety. However, it is not as outclassed as you might assume.
A recent study comparing extended-release trazodone with SSRIs in patients with major depressive disorder found that trazodone provided greater improvements in several quality-of-life measures, including the anxiety and depression dimensions of a widely used health assessment tool.7PubMed Central. Trazodone effectiveness in depression: impacts of trazodone extended release vs SSRIs on the health status and quality of life of patients with major depressive disorder That study focused on depression rather than a primary anxiety disorder, so it doesn’t directly prove that trazodone is better for standalone anxiety. But it does suggest that when anxiety accompanies depression, trazodone holds up well against the drugs most commonly used to treat both.
The practical distinction often comes down to side-effect profiles. SSRIs commonly cause sexual dysfunction, weight gain, and an initial period of increased nervousness. Trazodone’s main side effects lean toward sedation, dizziness, and low blood pressure. For someone whose anxiety is worst at night or who also struggles with insomnia, trazodone’s sedating quality is a feature rather than a bug. For someone who needs to stay sharp during the day, it can be a dealbreaker.
Trazodone for PTSD-Related Anxiety and Nightmares
One area where trazodone has carved out a practical role is in managing nightmares and sleep disruption tied to post-traumatic stress disorder. Nightmares are among the most treatment-resistant symptoms of PTSD, and they feed a cycle of sleep deprivation and heightened daytime anxiety that can be brutally hard to break. Trazodone is listed among medications with at least some evidence for managing PTSD-associated nightmares, alongside drugs like prazosin and certain atypical antipsychotics.8PubMed. Pharmacological Management of Nightmares Associated with Posttraumatic Stress Disorder
In a clinical survey of 60 patients with PTSD, 72% reported that trazodone was helpful in reducing nightmares, with the average number of nightmare-disrupted nights dropping from about 3.3 to 1.3 per week. An even higher proportion, 92%, said it helped with falling asleep, and 78% reported better sleep maintenance throughout the night.9PubMed. Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares These are not numbers from a placebo-controlled trial, so they should be read with some caution. But the consistency of the benefit, and the fact that it addresses the nighttime component of PTSD that many first-line treatments struggle with, explains why clinicians continue to reach for trazodone in this context. It is rarely used alone for PTSD, more often as an add-on to an SSRI or trauma-focused therapy, but the sleep and nightmare improvements can meaningfully reduce the overall anxiety burden.
When Anxiety and Insomnia Overlap
For many people, anxiety and insomnia are so intertwined that treating one without addressing the other feels futile. You lie awake worrying, the sleep loss makes you more anxious the next day, and the cycle repeats. Trazodone’s appeal in this scenario is that it can address both problems with a single medication. Its efficacy for insomnia has been repeatedly demonstrated in both people with depression and those without it, and this benefit extends to insomnia driven by a range of underlying conditions.10PubMed Central. Trazodone for Insomnia: A Systematic Review
The catch is that a dose low enough to serve primarily as a sleep aid may not do much for the anxiety itself, as discussed earlier. Clinicians sometimes start with a low bedtime dose and titrate upward, watching for both improved sleep and reduced daytime anxiety. This gradual approach can work well but requires patience and close follow-up, since the sedation at higher doses can leave people groggy well into the morning.
Fall Risk and Blood Pressure Concerns in Older Adults
Trazodone’s alpha-1 receptor blockade, the same property that helps calm the physical symptoms of anxiety, also lowers blood pressure. In younger, otherwise healthy adults this is usually a mild nuisance: a moment of dizziness when standing up too fast. In older adults, especially those already taking blood pressure medication, the effect can be dangerous. A study of geriatric outpatients with hypertension found that trazodone users experienced significantly larger drops in blood pressure upon standing. The incidence of fainting and falls in that group was about 58%, compared with roughly 21% in non-users.11PubMed Central. Trazodone and Risk of Orthostatic Hypotension, Syncope and Falls in Geriatric Outpatients with Hypertension Trazodone use predicted falls independently of age, disability, and fall history, though the association became less clear when researchers adjusted for dementia.
A broader study of long-term care residents confirmed that new users of trazodone, along with users of SSRIs and SNRIs, had a higher risk of fall-related emergency department visits or hospitalizations compared to residents not on antidepressants.12PubMed. Association between Antidepressants and Fall-Related Injuries among Long-Term Care Residents This does not mean older adults should never take trazodone for anxiety, but it does mean the risk-benefit calculation is different for a 78-year-old with high blood pressure than for a 35-year-old. Starting at the lowest possible dose, standing up slowly, and keeping the prescriber informed about any dizziness are basic but important precautions.
Trazodone During Alcohol Recovery
Anxiety and sleep problems are nearly universal during recovery from alcohol dependence, and trazodone sometimes gets prescribed in this context because it avoids the dependence risk of benzodiazepines. There is some case-level evidence suggesting trazodone can help with acute withdrawal symptoms, and it has shown short-term benefits for sleep quality after detoxification.13PubMed. Successful treatment of alcohol withdrawal with trazodone
However, a double-blind, placebo-controlled trial raised a concerning signal. While trazodone improved sleep in the short term after alcohol detoxification, it may have actually impeded improvements in drinking behavior. Patients who took trazodone showed increased drinking when the medication was stopped, compared to those on placebo. The researchers concluded that routine initiation of trazodone for sleep disturbance after alcohol detoxification cannot be recommended with confidence until further studies clarify the risks.14PubMed Central. Trazodone For Sleep Disturbance After Alcohol Detoxification: A Double-Blind, Placebo-Controlled Trial If you are in recovery and your doctor has prescribed trazodone for anxiety or sleep, this is worth a conversation but not necessarily a reason to refuse the medication, particularly if the alternative is a benzodiazepine, which carries its own serious risks in this population.
What About Children and Teenagers
Trazodone is sometimes prescribed to children and adolescents, most often for sleep problems associated with ADHD or anxiety. This is entirely off-label, and the evidence base is essentially nonexistent. A review of Medicaid prescribing in Oregon found that children with ADHD were receiving trazodone for conditions where no national guidelines or clinical evidence of efficacy supported its use.15PubMed Central. Trazodone Prescribing for Children With Attention Deficit Hyperactivity Disorder on Medicaid in Oregon The absence of evidence is not evidence of absence, and some clinicians report anecdotal success, but parents should understand that pediatric trazodone prescribing for anxiety is driven by clinical judgment rather than trial data.
Stopping Trazodone and Withdrawal Symptoms
Trazodone is often portrayed as a “safer” option partly because it lacks the physical dependence associated with benzodiazepines. This is broadly true, but it does not mean you can stop taking it abruptly without consequences. A large meta-analysis of antidepressant withdrawal found that across all antidepressant classes, roughly 43% of patients experienced some withdrawal symptoms after discontinuation. The risk increased with longer treatment duration: about 35% after 6 to 12 weeks of use, rising to over 51% after six months or more. Tapering the dose reduced symptoms compared to stopping abruptly, though the difference was not statistically significant in pooled data.16Nature. Incidence and risk factors of antidepressant withdrawal symptoms: a meta-analysis and systematic review
Trazodone withdrawal is generally less severe than withdrawal from SSRIs or tricyclic antidepressants, but it can still produce insomnia, irritability, and a rebound of anxiety symptoms that feel worse than the original problem. A gradual taper over two to four weeks is standard practice. If you have been taking trazodone at higher doses or for several months, do not stop on your own without discussing a tapering plan.
Serotonin Syndrome and Drug Interactions
Because trazodone increases serotonin activity, combining it with other serotonergic drugs raises the risk of serotonin syndrome, a potentially life-threatening condition involving agitation, rapid heart rate, high body temperature, and muscle rigidity. A systematic overview of antidepressant drug interactions found that about a quarter of identified interactions were of major clinical significance, with serotonin syndrome and hypertensive emergencies being the most common serious outcomes. Monoamine oxidase inhibitors posed the greatest risk, but SSRIs, certain pain medications like tramadol, and migraine drugs called triptans can also push serotonin levels dangerously high when combined with trazodone.17PubMed Central. Systematic overview of drug interactions with antidepressant medications
If you are already on an SSRI for anxiety and a clinician adds low-dose trazodone for sleep, the combination is used frequently and is usually safe at standard doses. But it is a combination that requires monitoring, and you should always tell every prescriber about every medication you are taking, including supplements like St. John’s wort that can affect serotonin pathways.
Why Trazodone Remains in a Regulatory Gray Zone
The fact that trazodone has never been formally approved for anxiety or insomnia, despite decades of widespread use for both, says less about the drug than about how pharmaceutical regulation works. Getting FDA approval for a new indication requires costly clinical trials, and trazodone’s patent expired long ago. No company has a financial incentive to fund the large-scale trials that would be needed to add anxiety or insomnia to the label. The result is a drug that clinicians prescribe routinely for conditions where the supporting evidence, while not negligible, has never been formally vetted by the regulatory process.18PubMed. Off-Label Trazodone Prescription: Evidence, Benefits and Risks
This gray zone is not unique to trazodone. Many psychiatric medications are prescribed off-label for conditions where the evidence supports their use but no company has pursued formal approval. For patients, the practical question is whether the evidence is strong enough to justify trying it, and that depends heavily on the specific anxiety condition, the dose range being considered, what else has been tried, and whether the sedating profile is a help or a hindrance in your particular situation.